

GM1 Gangliosidosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/G8C32C7639D2EN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: G8C32C7639D2EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

Global GM1 Gangliosidosis Market, Analysis and Forecast: 2025-2035

The global GM1 gangliosidosis market is witnessing substantial growth, driven by the increasing prevalence of genetic disorders, heightened awareness about rare diseases, and advancements in gene therapies, enzyme replacement therapies (ERT), and substrate reduction therapies (SRT). GM1 gangliosidosis, a rare and severe genetic disorder that affects the central nervous system, continues to impact a small, significant patient population worldwide. As the incidence of GM1 gangliosidosis rises, particularly due to greater recognition and improved genetic screening, the demand for effective and curative treatments is growing.

Growth in the GM1 gangliosidosis market is supported by the increasing recognition of the condition's impact on patients' quality of life, particularly in its more severe forms, which can lead to neurological decline and premature death if left untreated. The market is evolving as healthcare providers and pharmaceutical companies focus on early diagnosis and intervention, offering more treatment options to improve patient outcomes and reduce disease progression. Key therapeutic categories include gene therapies, which aim to correct genetic mutations; enzyme replacement therapies; and substrate reduction therapies, all of which are gaining attention for their potential to address the underlying causes of the disease.

Improved healthcare infrastructure in emerging markets, increasing awareness among patients and healthcare providers, and enhanced access to genetic testing and treatment options are significant contributors to market growth. Furthermore, favourable reimbursement policies in developed regions are enabling greater access to advanced therapies, which further drives market expansion. The ongoing development of personalized medicine, particularly gene therapies tailored to individual patient profiles, is expected to open new opportunities for market growth, offering more precise and effective treatment options for patients.

Advancements in drug delivery technologies, such as AAV-based gene therapies, CRISPR gene editing techniques, and innovative enzyme replacement formulations, are playing a crucial role in expanding the therapeutic landscape for GM1 gangliosidosis. These innovations are designed to improve treatment efficacy, enhance patient adherence, and minimize side effects, which are key challenges in current therapeutic options. Personalized medicine, which takes into account genetic factors and individual patient profiles, is expected to revolutionize the management of GM1 gangliosidosis by offering more targeted and effective therapies.

Despite promising growth prospects, the GM1 gangliosidosis market faces several challenges. The high cost of gene therapies and other advanced treatments is a major restraint, as these therapies often come with significant financial burdens, limiting accessibility for many patients, especially in lower-income regions. Additionally, the complexity of the disease, particularly the difficulty in delivering therapies to the brain due to the blood-brain barrier, presents a significant challenge in ensuring efficacy. Regulatory hurdles and lengthy approval timelines for new treatments may also delay the availability of breakthrough therapies, further impacting market dynamics.

The competitive landscape of the GM1 gangliosidosis treatment market is characterized by the active involvement of leading biotechnology companies, pharmaceutical firms, and research institutions. Strategic partnerships, collaborations, and acquisitions are common as stakeholders seek to enhance their product portfolios and accelerate research into more effective treatments. Investments in research and development, particularly in gene therapies, drug delivery systems, and novel enzyme replacement therapies, will play a critical role in shaping the future of the market, aiming to improve clinical outcomes and provide better patient-centric care.

Looking forward, the global GM1 gangliosidosis market is poised to continue its growth, driven by the rising recognition of the disease, advancements in treatment modalities,

and a growing emphasis on early diagnosis and intervention. The integration of digital health technologies, such as genetic screening tools and patient tracking systems, is expected to improve disease management and facilitate better treatment adherence. With continued focus on personalized medicine and the development of innovative therapeutic options, the GM1 gangliosidosis market is positioned to improve patient outcomes and quality of life, offering hope to individuals and families affected by this rare and devastating genetic disorder.

Market Segmentation:

Segmentation 1: by Region

North America

Europe

Asia-Pacific

Rest-of-the-World

The GM1 gangliosidosis market is poised for significant growth, driven by advancements in gene therapies, enzyme replacement therapies (ERT), and substrate reduction therapies. As awareness of GM1 gangliosidosis continues to rise, particularly in regions with growing genetic screening programs, demand for effective and curative treatments is expected to increase. Additionally, the development of innovative delivery systems for gene therapies, such as overcoming the blood-brain barrier, will propel market expansion. The rising focus on early diagnosis, supported by advancements in genetic testing, will enable earlier interventions and improve patient outcomes. Regulatory incentives for orphan drugs and favorable reimbursement policies will further support market growth. With continued research, patient advocacy, and the development of personalized therapies, the GM1 gangliosidosis market is well-positioned to address the growing need for specialized and targeted treatment options.

Regions Covered

North America

U.S.

Canada

Europe

Germany

Italy

France

U.K.

Spain

Rest-of-Europe

Asia-Pacific

Japan

China

India

South Korea

Australia

Rest-of-Asia-Pacific

Rest-of-the-World

Latin America

Middle East and Africa

Companies Mentioned

Axovant Gene Therapies Ltd.
CRISPR Therapeutics AG
Gain Therapeutics, Inc.
Gemma Biotherapeutics Inc.
Lysogene S.A.
Orchard Therapeutics plc
Passage Bio, Inc.
REGENXBIO Inc.
Sio Gene Therapies Inc.
Takeda Pharmaceutical Company Limited

Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. GLOBAL GM1 GANGLIOSIDOSIS MARKET: INDUSTRY ANALYSIS

1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
 1.3.1 Impact Analysis
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
 1.6.1 Overview
 1.6.2 Market Drivers
 1.6.3 Market Restraints
 1.6.4 Market Opportunities

2. GLOBAL GM1 GANGLIOSIDOSIS MARKET (BY REGION), VALUE (\$MILLION), 2023-2035

2.1 North America
 2.1.1 Market Dynamics
 2.1.2 Market Sizing and Forecast
 2.1.3 North America GM1 Gangliosidosis Market, by Country (\$Million), 2023-2035
 2.1.3.1 U.S.
 2.1.3.2 Canada
2.2 Europe
 2.2.1 Market Dynamics
 2.2.2 Market Sizing and Forecast
 2.2.3 Europe GM1 Gangliosidosis Market, by Country (\$Million), 2023-2035
 2.2.3.1 U.K.
 2.2.3.2 France
 2.2.3.3 Germany

2.2.3.4 Italy

2.2.3.5 Spain

2.2.3.6 Rest-of-Europe

2.3 Asia-Pacific

2.3.1 Market Dynamics

2.3.2 Market Sizing and Forecast

2.3.3 Asia-Pacific GM1 Gangliosidosis Market, by Country (\$Million), 2023-2035

2.3.3.1 Japan

2.3.3.2 China

2.3.3.3 India

2.3.3.4 Australia

2.3.3.5 South Korea

2.3.3.6 Rest-of-Asia-Pacific

2.4 Rest-of-the-World

2.4.1 Market Dynamics

2.4.2 Market Sizing and Forecast

2.4.3 Rest-of-the-World GM1 Gangliosidosis Market, by Country (\$Million), 2023-2035

2.4.3.1 Latin America

2.4.3.2 Middle East and Africa

3. COMPETITIVE LANDSCAPE AND COMPANY PROFILES

3.1 Competitive Landscape

3.1.1 Mergers and Acquisitions

3.1.2 Partnership, Alliances and Business Expansion

3.1.3 New Offerings

3.1.4 Regulatory Activities

3.1.5 Funding Activities

3.2 Company Profiles

3.2.1 Axovant Gene Therapies Ltd.

3.2.1.1 Overview

3.2.1.2 Top Products / Product Portfolio

3.2.1.3 Top Competitors

3.2.1.4 Target Customers/End-Users

3.2.1.5 Key Personnel

3.2.1.6 Analyst View

3.2.2 CRISPR Therapeutics AG

3.2.2.1 Overview

3.2.2.2 Top Products / Product Portfolio

- 3.2.2.3 Top Competitors
- 3.2.2.4 Target Customers/End-Users
- 3.2.2.5 Key Personnel
- 3.2.2.6 Analyst View
- 3.2.3 Gain Therapeutics, Inc.
 - 3.2.3.1 Overview
 - 3.2.3.2 Top Products / Product Portfolio
 - 3.2.3.3 Top Competitors
 - 3.2.3.4 Target Customers/End-Users
 - 3.2.3.5 Key Personnel
 - 3.2.3.6 Analyst View
- 3.2.4 Gemma Biotherapeutics Inc.
 - 3.2.4.1 Overview
 - 3.2.4.2 Top Products / Product Portfolio
 - 3.2.4.3 Top Competitors
 - 3.2.4.4 Target Customers/End-Users
 - 3.2.4.5 Key Personnel
 - 3.2.4.6 Analyst View
- 3.2.5 Lysogene S.A.
 - 3.2.5.1 Overview
 - 3.2.5.2 Top Products / Product Portfolio
 - 3.2.5.3 Top Competitors
 - 3.2.5.4 Target Customers/End-Users
 - 3.2.5.5 Key Personnel
 - 3.2.5.6 Analyst View
- 3.2.6 Orchard Therapeutics plc
 - 3.2.6.1 Overview
 - 3.2.6.2 Top Products / Product Portfolio
 - 3.2.6.3 Top Competitors
 - 3.2.6.4 Target Customers/End-Users
 - 3.2.6.5 Key Personnel
 - 3.2.6.6 Analyst View
- 3.2.7 Passage Bio, Inc.
 - 3.2.7.1 Overview
 - 3.2.7.2 Top Products / Product Portfolio
 - 3.2.7.3 Top Competitors
 - 3.2.7.4 Target Customers/End-Users
 - 3.2.7.5 Key Personnel
 - 3.2.7.6 Analyst View

3.2.8 REGENXBIO Inc.

3.2.8.1 Overview

3.2.8.2 Top Products / Product Portfolio

3.2.8.3 Top Competitors

3.2.8.4 Target Customers/End-Users

3.2.8.5 Key Personnel

3.2.8.6 Analyst View

3.2.9 Sio Gene Therapies Inc.

3.2.9.1 Overview

3.2.9.2 Top Products / Product Portfolio

3.2.9.3 Top Competitors

3.2.9.4 Target Customers/End-Users

3.2.9.5 Key Personnel

3.2.9.6 Analyst View

3.2.10 Takeda Pharmaceutical Company Limited

3.2.10.1 Overview

3.2.10.2 Top Products / Product Portfolio

3.2.10.3 Top Competitors

3.2.10.4 Target Customers/End-Users

3.2.10.5 Key Personnel

3.2.10.6 Analyst View

3.2.11 Others

4. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Global GM1 Gangliosidosis Market Coverage

Figure: Global GM1 Gangliosidosis Market Key Trends, Impact Analysis, 2023-2035

Figure: Global GM1 Gangliosidosis Market, Patent Analysis, January 2022-May 2025

List Of Tables

LIST OF TABLES

Table: Global GM1 Gangliosidosis Market (by Region), \$Million, 2023-2035

I would like to order

Product name: GM1 Gangliosidosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/G8C32C7639D2EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8C32C7639D2EN.html>